At Catalyst our mission is to develop and commercialize innovative therapies for people with rare debilitating neuromuscular and neurological diseases. To execute this mission, we gather the best ideas, utilize leading-edge science, and partner with leaders in their respective fields.
Catalyst is continually seeking strong, strategic partnerships that will further the development and commercialization of innovative therapies. For additional information on these partnering opportunities, please contact Catalyst Pharmaceuticals.
Catalyst and BioMarin Strategic Collaboration
Catalyst entered into a strategic collaboration with BioMarin regarding amifampridine phosphate. The key components of the collaboration included: (1) Catalyst Pharmaceuticals licensing the exclusive North American rights to amifampridine phosphate; (2) BioMarin making a $5,000,000 investment in the Company pursuant to the terms of a Convertible Promissory Note and Note Purchase Agreement, which has been converted into 6,666,667 shares of the Company’s authorized but unissued common stock; and (3) Catalyst assuming development responsibility for amifampridine phosphate in the North American markets.
The US FDA approved Firdapse® (amifampridine) tablets for use in adults with LEMS on November 28, 2018, and Catalyst began its commercial launch in early 2019.
New York University (NYU) and the Feinstein Institute for Medical Research (FIMR)
On December 13, 2011, the Company entered into a license agreement with NYU and the FIMR, under which it acquired worldwide rights to commercialize GABA aminotransferase inhibitors in the treatment of Tourette’s syndrome, a patent pending indication for which Catalyst is a co-inventor. The Company is obligated to pay certain milestone payments in future years relating to clinical development activities and royalties on any products resulting from the license agreement.